Table 1.

Patient characteristics, history of prostate cancer and outcome from lymphadenectomies from 23 patients undergoing lymphadenectomy

Parameters	Values
iPSA at primary therapy (ng/ml)
Mean ± SD/median/range	10.79 ± 7.5/8.8/3.37–37.0
Primary therapy, n
Radical prostatectomy	21/23 (91.3%)
Radiotherapy	2/23 (8.7%)
Gleason score, n
7a	4 (17%)
7b	7 (31%)
8	5 (22%)
9	7 (30%)
111In-PSMA-guided LA overall, n
Primary	2/23 (8.7%)
Salvage lymph node dissection	21/23 (91.3%)
Age at lymphadenectomy (years)
Mean ± SD/median/range	67.5 ± 6.6/67/52–78
PSA at 111In-PSMA-guided LA (ng/ml)
Mean ± SD/median/range	7.9 ± 12.9/1.8/0.03–56.2
Time between PET/CT and 111In-PSMA-guided LA (months)
Mean ± SD/median/range	3.2 ± 1.6/3.0/1.0–8.0
Time between primary therapy and 111In-PSMA-guided LA (years) (n = 21)
Mean ± SD/median/range	4.9 ± 3.7/4.4/1.5–13.7
Histological outcome for 23 patients, n
LA with positive histology	21/23 (91.3%)
LA with negative histology	2/23 (8.7%)
Topography of 111In-PSMA-guided LA in 23 patients, n
Pelvic right and left	13/23 (57%)
Pelvic left only	2/23 (9%)
Pelvic right only	1/23 (4%)
Pelvic right and left and retroperitoneal	7/23 (30%)
Topography of subregions with confirmed PCa, n
Pelvic left, n	38/275 (37%)
Pelvic right, n	41/275 (40%)
Retroperitoneal	24/275 (23%)
Histological outcome for 275 subregions with 275 samples, n
Subregions/samples with LNM	104/275 (37.5%)
Subregions/samples without LNM	171/275 (62.5%)
Subregions/samples with additional non-nodal PCa-tissue	7/104 (5.8%)
Number of LN removed (n)
Overall	864
Per patient (mean ± SD/median/range)	37.6 ± 17.2/38.0/2.0–82.0
Number of LNM removed (n)
Overall	197
Per patient (mean ± SD/median/range)	8.6 ± 14.9/4.0/0.0–71.0
LNM fraction per patient (LNM×100/LN = %)
Mean ± SD/median/range	20.9 ± 24.4/12.5/0.0–87.1

LNM lymph node metastases, LN lymph node, PSA prostate-specific antigen, LA lymphadenectomy